Biogen stock plummets 28% after halting Alzheimer’s trials
March 21, 2019 at 09:37 AM EDT
Shares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an investigational drug designed to treat symptoms of early Alzheimer’s disease.